Ryder's Q3 earnings beat expectations despite flat revenue, with mixed segment results and plans for continued growth.
Trump's $300M White House ballroom project sparks backlash over cost, historic preservation concerns
Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Ryder's Q3 earnings beat expectations despite flat revenue, with mixed segment results and plans for continued growth.
Trump's $300M White House ballroom project sparks backlash over cost, historic preservation concerns
Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.